Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

By News Health
2 days Ago

(MedPage Today) — CHICAGO — The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115827

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Pharmacists warn drug shortage affecting cancer patients

Tumor Treating Fields Boost Pancreatic Cancer Survival

Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?